

NCTN Gastrointestinal Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.




NCTN Gastrointestinal Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Gastrointestinal Cancer Trials (Open as of 11/15/2025)

| Phase | Protocol Title |
|--------|--|
| Ш | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer |
| | A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic |
| Ш | Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) |
| | Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of |
| Ш | Metastatic HER2-Negative Gastroesophageal Adenocarcinoma |
| | Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic |
| 11/111 | Pancreatic Ductal Adenocarcinoma (PLATINUM) |
| | The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus |
| Ш | ChemoRadioTherapy for Early Rectal Cancer |
| | NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable |
| П | Midgut NET |
| | A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and |
| 11/111 | Gastroesophageal Junction Adenocarcinoma |
| | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in |
| II | Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation |
| | A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable |
| Ш | Colorectal Liver Metastases: The PUMP Trial |
| | A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in |
| 11/111 | Gastric Carcinomatosis - STOPGAP II |
| Ш | A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma |
| Ш | Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) |
| II/III | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) |
| | A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients |
| Ш | (LAP100) |
| | Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with |
| Ш | Macrovascular Invasion (HELIO-RT) |
| | Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel |
| H | Adenocarcinoma |
| | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in |
| 11/111 | Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) |
| | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High- |
| П | Risk Pancreatic Neuroendocrine Tumors |
| | Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in |
| 11/111 | Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) |
| Other | Molecular Analysis for Combination Therapy Choice (ComboMATCH) |
| | A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A |
| П | ComboMATCH Treatment Trial |
| | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, |
| | in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial |
| Ш | In Patients with HEK2+ Gynecologic Cancers and Other Solid Tumors: A CompoNIATCH Treatment Trial |
| | III III III III III III III III III II |